Fiche publication
Date publication
janvier 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc
,
Pr ENTZ-WERLE Natacha
Tous les auteurs :
Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Berard P
Lien Pubmed
Résumé
BACKGROUND: The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) national registry. METHODS: All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed. RESULTS: Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The median age at the beginning of treatment was 19 years (range 9-72). The median number of previous lines of chemotherapy was 3 (range 1-8). Before inclusion, 3 patients were in second complete remission, 26 were in progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5 % of patients (95 % Confidence Interval (CI) [20-52.8]). The median Progression-Free Survival (PFS) was 3 months (95 % CI [2-5.4]) for patients treated by sirolimus and 1.8 months (95 % CI [1.3-2.8]) for patients receiving multi-targeted tyrosine kinase inhibitors; 6-month PFS 15 %. The median Overall Survival (OS) was 6.8 months (95 % CI [4.7-12.1]), and one-year OS was 24 %. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to other TTs (Hazard Ratio (HR) = 2.7, 95 % CI [1.05-7.1]). No toxic death was reported. Grade 3 and 4 toxicities were observed in 27 and 6 % of cases respectively. CONCLUSION: Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with an acceptable toxicity profile, including in pediatric population.
Référence
BMC Cancer. 2015 Nov 5;15(1):854
